F
Freddy G. Eliaschewitz
Researcher at Pfizer
Publications - 4
Citations - 3681
Freddy G. Eliaschewitz is an academic researcher from Pfizer. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 3, co-authored 3 publications receiving 2716 citations.
Papers
More filters
Journal ArticleDOI
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P. Marso,Stephen C. Bain,A. Consoli,Freddy G. Eliaschewitz,Esteban Jódar,Lawrence A. Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,O Hansen,Anders G. Holst,Jonas Pettersson,Tina Vilsbøll +14 more
TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.
Journal ArticleDOI
Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes
Julio Rosenstock,William T. Cefalu,Priscilla A. Hollander,André Bélanger,Freddy G. Eliaschewitz,Jorge Luiz Gross,Solomon S. Klioze,Lisa St Aubin,Howard Foyt,Masayo Ogawa,William T. Duggan +10 more
TL;DR: Two-year prandial EXU therapy showed a small nonprogressive difference in FEV1 and comparable sustained A1C improvement but lower FPG levels and less weight gain than seen in association with subcutaneous insulin in adults with type 2 diabetes.
Journal ArticleDOI
Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.
Julio Rosenstock,Freddy G. Eliaschewitz,Cory R. Heilmann,Douglas B. Muchmore,Risa P. Hayes,Ruth M. Belin +5 more
TL;DR: Preprandial inhaled insulin provides an alternative for patients not optimized on insulin glargine alone, and Glycemic control, hypoglycemic risk, delivery preference, and regimen complexity must be considered when selecting insulin initiation and optimization regimens.
Journal ArticleDOI
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Maurício Reis Pedrosa,Denise Reis Franco,Hannah Waisberg Gieremek,Camila Maia Vidal,Fernanda Bronzeri,Alexia de Cassia Rocha,Luis Gabriel de Carvalho Cara,Sofia Lenzi Fogo,Freddy G. Eliaschewitz +8 more
TL;DR: Clinical studies highlight that GLP-1RA to treat obesity, alongside their concomitant cardioprotective effects, have become a hallmark in clinical science.